Evidence map›Paper›PMID 19065650›Full record

ReviewHepatology (Baltimore, Md.)2009

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.

Raj Vuppalanchi, Naga Chalasani

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hepatology (Baltimore, Md.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04081571 (Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study), which is not on this map. Cited by 235 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04081571 unknown statusnot on this mapstarted 2019, after this paper: background citation

Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study

TypeobservationalSponsorCairo UniversityRan2019 to 2023Enrolled1,080ConditionsNAFLD, Insulin Resistance, Hepatic Steatosis
3 · Its place in the literature

Who cites it

235 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. The dynamic spectrum of steatotic liver disease: the global perspective.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

175 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Raj VuppalanchiDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Naga Chalasani

Funding

Patient-Oriented Research of Liver DiseaseK24DK069290 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI CHALASANI, NAGA P · 2005 to 2014
$1.4M
NIDDK NIH HHS K24 DK069290NIDDK NIH HHS K24 DK072101
6 · The paper itself

Abstract

unlabelledNonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the western world. It is now recognized that these patients have myriad of important co-morbidities (e.g., diabetes, hypothyroidism and metabolic syndrome). The workup of patients with suspected NAFLD should consist of excluding competing etiologies and systemic evaluation of metabolic comorbidities. NAFLD is histologically categorized into steatosis and steatohepatitis, two states with fairly dichotomous natural history. While significant progress has been made in terms of noninvasively predicting advanced fibrosis, insufficient progress has been made in predicting steatohepatitis. Currently, liver biopsy remains the gold standard for the histological stratification of NAFLD. While sustained weight loss can be effective to treat NASH, it is often difficult to achieve. Foregut bariatric surgery can be quite effective in improving hepatic histology in selected patients without liver failure or significant portal hypertension. Thiazolidinediones have shown promise and the results from the ongoing, large multicenter study should become available soon. Large multicenter studies of CB, receptor anatagonists are also underway but their results will not be available for several years. Several recent studies have highlighted that cardiovascular disease is the single most important cause of morbidity and mortality in this patient population.

conclusionHealth care providers should not only focus on liver disease but also concentrate on aggressively modifying and treating their cardiovascular risk factors.

Indexed as

Bariatric SurgeryBiomarkersBiopsyCardiovascular DiseasesComorbidityDiabetes Mellitus, Type 2DyslipidemiasExerciseFatty LiverHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLiverLiver CirrhosisLiver DiseasesMetabolic SyndromeMetforminBiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsMetforminPioglitazoneRosiglitazoneThiazolidinediones

Identifiers

PMID19065650
PMCPMC2766096

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.